A5032596712- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer Research and Treatments
- CAR-T cell therapy research
- PARP inhibition in cancer therapy
- Cancer Cells and Metastasis
- Pancreatitis Pathology and Treatment
- Neuroendocrine Tumor Research Advances
- Immune cells in cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Helicobacter pylori-related gastroenterology studies
- Gastric Cancer Management and Outcomes
- Nutrition and Health in Aging
- Phagocytosis and Immune Regulation
- Advanced Breast Cancer Therapies
- Immune Cell Function and Interaction
- Cancer, Stress, Anesthesia, and Immune Response
- Immunotherapy and Immune Responses
- Muscle activation and electromyography studies
- Biosimilars and Bioanalytical Methods
- Non-Invasive Vital Sign Monitoring
Monash University
2018-2025
Peninsula Health
2020-2025
Monash Health
2019-2024
Hudson Institute of Medical Research
2018-2024
Frankston Hospital
2022
Monash Medical Centre
2017-2018
Launceston General Hospital
2017
U-M Rogel Cancer Center
2016
Peter MacCallum Cancer Centre
2016
St Vincent's Hospital
2016
Purpose: Pancreatic ductal adenocarcinoma (PDAC) has the lowest five-year survival rate of all cancers in United States. Programmed death 1 receptor (PD-1)-programmed ligand (PD-L1) immune checkpoint inhibition been unsuccessful clinical trials. Myeloid-derived suppressor cells (MDSCs) are known to block anti-tumor CD8+ T cell responses various including pancreas. This led us our objective that was develop a clinically relevant vitro organoid model specifically target mechanisms deplete...
Background: KRAS G12D mutation subtype is present in over 40% of pancreatic ductal adenocarcinoma (PDAC), one the leading global causes cancer death. This retrospective cohort study aims to investigate whether detection PDAC patients a determinant prognosis across all stages disease. Methods: We reviewed medical records 231 presenting with at large tertiary hospital, and compared survival using Kaplan Meier, log-rank test Cox proportional hazards regression model. Results: was not...
Pancreatic cancer is the third leading cause of cancer-related death in Australia, with a persistently poor 5-year survival rate around 13%. Symptoms arising from disease and chemotherapy such as epigastric pain, anorexia, bloating fat-malabsorptive diarrhoea oral intake weight loss, reduce an individual's quality life ability to tolerate anti-cancer treatment. The primary aim this study determine if early, intensive telehealth nutrition intervention can improve compared usual care for...
48 Background: The release of tumor-associated antigens may enhance the response to immunotherapy. BGB-A317, a humanized IgG4 variant monoclonal antibody engineered have no Fc gamma receptor binding, targets programmed cell death-1 (PD-1) receptor. It is being developed in solid and hematologic malignancies at dose 200 mg IV Q3W. BGB-290, potent inhibitor PARP 1/2, hypothesized promote neoantigen that potentially increase efficacy BGB-A317. A phase 1 study identified 60 BID as recommended...
Acute and chronic pancreatitis, the latter associated with fibrosis, are multifactorial inflammatory disorders leading causes of gastrointestinal disease-related hospitalization. Despite global health burden currently, there no effective therapeutic agents. In this regard, protease A Disintegrin And Metalloproteinase 17 (ADAM17) mediates responses through shedding bioactive cytokines mediators, including tumor necrosis factor α (TNFα) soluble interleukin (IL)-6 receptor (sIL-6R), which...
3013 Background: The release of tumor-associated antigens may enhance the response to immunotherapy. BGB-A317, a humanized IgG4 variant monoclonal antibody engineered have no Fc gamma receptor binding, targets programmed cell death-1 (PD-1) receptor. It is being developed in solid and hematologic malignancies at dose 200 mg IV Q3W. BGB-290, potent inhibitor PARP 1/2, hypothesized promote neoantigen that will potentially increase efficacy BGB-A317. A phase 1 study identified 60mg BID as...
Low skeletal muscle index (SMI) and low radiodensity (SMD) are associated with reduced survival time in pancreatic ductal adenocarcinoma (PDAC). The negative prognostic impact of SMI SMD is often reported as independent cancer stage when using traditional clinical staging tools. Therefore, this study sought to explore the relationship between a novel marker tumour burden (circulating DNA) abnormalities at diagnosis PDAC. A retrospective cross-sectional was conducted patients who had plasma...
3557 Background: Pts with BRAFm mCRC have an exceedingly poor prognosis. Unlike melanoma, BRAF inhibitor monotherapy has limited activity in mCRC. Preclinically, inhibition results rapid feedback activation of EGFR and ongoing tumor proliferation, which can be readily overcome by combining inhibition. EViCT examined the safety efficacy two oral agents targeting Vemurafenib (Vem) Erlotinib (Erl), pts. Herein, we report preliminary data. Methods: had 2 parts: a Phase I dose escalation Erl...
Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis, and current diagnostic tests have suboptimal sensitivity. Incorporating standard cytology targeted transcriptomic mutation analysis may improve upon the accuracy of biopsies, thus reducing burden repeat procedures delays to treatment initiation. Experimental Design: We reviewed 308 endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) PDAC biopsies using large multicenter...
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death and lacks effective treatment options. Diagnostic endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) biopsies represent an appealing source material for molecular analysis to inform targeted therapy, as they are often the only available tissue patients presenting with PDAC irrespective disease stage. However, EUS-FNA typically not used screen precision medicine studies due concerns about low yield quality....
Patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (A-PDAC) are not candidates for surgical resection and often offered palliative chemotherapy. The ready availability of a safe effective tumor sampling technique to provide material both diagnosis comprehensive genetic profiling is critical informing precision medicine in A-PDAC, thus potentially increasing survival. aim this study examine the feasibility benefits routine genomic (CGP) A-PDAC using EUS-FNA...
2593 Background: The novel small molecule CCX559 is a highly potent and selective PD-L1 inhibitor that induces the dimerization internalization of cell-surface PD-L1. CCX559, when orally administered in animal models, demonstrated anti-tumor efficacy, including ability to induce complete responses (Li C, et al. Cancer Res 2021;81(13_Suppl): Abstract nr 1274). Safety pharmacology toxicology studies animals an acceptable safety profile for CCX559. Taken together, preclinical data supports...